GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (HKSE:00460) » Definitions » Cash Flow from Financing

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Cash Flow from Financing : HK$-459 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Sihuan Pharmaceutical Holdings Group paid HK$0 Mil more to buy back shares than it received from issuing new shares. It spent HK$168 Mil paying down its debt. It paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$7 Mil from paying cash dividends to shareholders. It spent HK$41 Mil on other financial activities. In all, Sihuan Pharmaceutical Holdings Group spent HK$203 Mil on financial activities for the six months ended in Dec. 2023.


Sihuan Pharmaceutical Holdings Group Cash Flow from Financing Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Cash Flow from Financing Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -186.41 218.76 919.16 -266.82 -458.91

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 543.16 -573.45 279.49 -244.47 -214.44

Sihuan Pharmaceutical Holdings Group Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Sihuan Pharmaceutical Holdings Group's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Sihuan Pharmaceutical Holdings Group's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-459 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sihuan Pharmaceutical Holdings Group  (HKSE:00460) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Sihuan Pharmaceutical Holdings Group's issuance of stock for the six months ended in Dec. 2023 was HK$0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Sihuan Pharmaceutical Holdings Group's repurchase of stock for the six months ended in Dec. 2023 was HK$0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Sihuan Pharmaceutical Holdings Group's net issuance of debt for the six months ended in Dec. 2023 was HK$-168 Mil. Sihuan Pharmaceutical Holdings Group spent HK$168 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Sihuan Pharmaceutical Holdings Group's net issuance of preferred for the six months ended in Dec. 2023 was HK$0 Mil. Sihuan Pharmaceutical Holdings Group paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Sihuan Pharmaceutical Holdings Group's cash flow for dividends for the six months ended in Dec. 2023 was HK$7 Mil. Sihuan Pharmaceutical Holdings Group received HK$7 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Sihuan Pharmaceutical Holdings Group's other financing for the six months ended in Dec. 2023 was HK$-41 Mil. Sihuan Pharmaceutical Holdings Group spent HK$41 Mil on other financial activities.


Sihuan Pharmaceutical Holdings Group Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (HKSE:00460) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.
Executives
Che Fengsheng 2201 Interest of corporation controlled by you
Guo Weicheng 2201 Interest of corporation controlled by you
Meng Xianhui 2201 Interest of corporation controlled by you
Zhang Jionglong 2201 Interest of corporation controlled by you
Mingyao Capital Limited 2401 A concert party to an agreement to buy shares
Network Victory Limited 2401 A concert party to an agreement to buy shares
Proper Process International Limited 2401 A concert party to an agreement to buy shares
Successmax Global Holdings Limited 2101 Beneficial owner
Victory Faith International Limited 2401 A concert party to an agreement to buy shares
Ubs Tc (jersey) Ltd 2301 Trustee
Ubs Trustees (cayman) Ltd. 2301 Trustee
Smart Top Overseas Limited 2501 Other
Plenty Gold Enterprises Limited 2307 Founder of a discretionary trust who can infl

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Headlines

No Headlines